# FDA Approves Chiesi's New Drug Application NDA219622 Chiesi Pharmaceuticals has received FDA approval for a new drug candidate under application NDA219622, marking an addition to the company's portfolio that could strengthen its market position in the pharmaceutical sector. The approval positions Chiesi to capture market share in the therapeutic area and may generate significant revenue streams as the company prepares for commercialization.